Hanson is a Director of FIRE1, Contego, Reprieve Cardiovascular, Half Moon Medical, Tangible Science, and Foundry Therapeutics 2.Ī medical device industry veteran with more than 25 years experience, before Regatta Medical, Chip was CEO of Creganna Medical, a leading Ireland based supplier to the minimally invasive medical device industry. Hanson is a named inventor on over 360 issued US patents. Before joining DVI, Hanson worked in engineering roles at Oximetrix and General Dynamics. From 1985-1990, Hanson worked at Devices for Vascular Intervention (acquired by Eli Lilly) in various engineering, clinical research and marketing capacities. In 1991, Hanson co-founded and served as President of Cardiovascular Therapeutic Technologies (acquired by Eli Lilly). In 1992-1993, Hanson co-founded and served as Managing Director of Bavaria Medizin Technologie, GmbH in Oberpfaffenhofen, Germany. From 1993-1998, he built and led a 62-person team at Heartport developing a wide variety of novel devices and procedures for minimally invasive cardiac surgery. Prior to The Foundry, Hanson was Vice President of Research and Development at Heartport, Inc., which had a successful IPO in 1996. Since its inception in 1998, Hanson has led The Foundry in all of its activities.
Hanson is also a Managing Partner at The Foundry, LLC, a medical device company incubator and a preferred partner to LSV.
He has served in this role since November 2013.
He assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvar Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson). Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. He focuses on medical device investments. Tak joined NEA in 2018 as a Principal on the healthcare team. He was a cardiothoracic surgeon in the UK and clinical lead for chest trauma, responsible for developing and running the chest trauma service at one of London's major trauma centers.
Alexandros mt sinai free#
Alexandros studied medicine at the Royal Free Hospital in London and followed on with higher surgical training in cardiothoracic and major trauma surgery. He has worked extensively with medical affairs and safety teams as well as European regulators and as a former Notified body in-house clinician, Alexandros is a subject matter expert on the new European Medical Device and In Vitro Diagnostic Regulations.
Alexandros mt sinai software#
He has a special interest in software as a medical device, wearables and device drug-device combination products.
Alexandros Charitou is an Associate Partner in the EY Global Life Sciences Practice, with more than 25 years of experience in healthcare and life sciences, he leads a team providing expertise and support across the MedTech product lifecycle, in strategic commercial assessments, clinical advisory, and regulatory strategy as well as patient safety.
0 kommentar(er)
